Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab versus oral migraine prophylactics in adult episodic migraine
2018-001228-20Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of erenumab, topiramate, propranolol, metoprolol, amitriptyline and 3 more in migraine and episodic migraine (2 arms), sponsored by Novartis. Primary endpoint: Sustained benefit at Month 12. Started Feb 2019; status: completed.
02
Drugs
erenumabtopiramatepropranololmetoprololamitriptyline
03
Conditions
migraineepisodic migraine
Beyond the preview
Go deeper on 2018-001228-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001228-20.